• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Editor's Pick More than 200 drugmakers led by Pfizer blast Texas judge’s abortion pill decision
Editor's Pick

More than 200 drugmakers led by Pfizer blast Texas judge’s abortion pill decision

by April 11, 2023
by April 11, 2023 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

More than 200 biopharma groups, which include a number of drugmakers led by Pfizer, have signed an open letter blasting the decision by Texas federal Judge Matthew Kacsmaryk to issue a hold on federal approval of mifepristone, the most commonly used method of abortion in the U.S.

The letter criticized Kacsmaryk for having issued the ruling despite having ‘no scientific training’ and said his decision has ‘undermined the bipartisan authority granted by Congress to the Food and Drug Administration to approve and regulate safe, effective medicines for every American.’

‘The decision ignores decades of scientific evidence and legal precedent,’ the drugmakers wrote. ‘Judge Kacsmaryk’s act of judicial interference has set a precedent for diminishing FDA’s authority over drug approvals, and in so doing, creates uncertainty for the entire biopharma industry.’

In addition to Pfizer CEO Albert Bourla, the letter was signed by representatives for Merck and Biogen, as well as industry nonprofit groups like the Center for Medicine in the Public Interest.  

In his ruling last week, Kacsmaryk sided with an anti-abortion group that had challenged the FDA’s decades-old approval of the drug.

‘The Court does not second-guess FDA’s decision-making lightly,’ Kacsmaryk wrote in his decision. ‘But here, FDA acquiesced on its legitimate safety concerns — in violation of its statutory duty — based on plainly unsound reasoning and studies that did not support its conclusions.’

The case is likely to make its way to the Supreme Court.

Separately, the primary lobbying arm of the pharmaceutical industry, PhRMA, issued a statement Monday saying Kacsmaryk’s ruling undermines the regulatory process.

‘The FDA is the gold standard for determining whether a medicine is safe and effective for people to use,’ the organization said. ‘While PhRMA and our members are not a party to this litigation, our focus is on ensuring a policy environment that supports the agency’s ability to regulate and provides access to FDA-approved medicines.’

This post appeared first on NBC NEWS
You Might Also Like
  • Inflation ticks upward to 3.7% in August as the Fed’s fight to tame high prices rolls on
  • Immersive entertainment company Cosm lands rights to broadcast NFL games
  • Buffett’s Berkshire Hathaway hits $1 trillion market value, first U.S. company outside of tech to do so
  • Musk still needs ‘Twitter sitter,’ judges rule
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Senate Democrats demand Chief Justice Roberts open investigation into Clarence Thomas over ‘misconduct’
next post
FBI warns against using public phone charging stations

You may also like

What Role Does Knowledge Management Play in an Organization?

December 3, 2022

Social Security recipients will see a cost-of-living increase of 3.2%...

October 13, 2023

Women’s college basketball final expected to set new viewership records...

April 6, 2024

Boeing to raise as much as $25 billion to shore...

October 16, 2024

Netflix inks deal to stream its first NFL games on...

May 16, 2024

The fight for the future of the Murdoch media empire...

September 10, 2024

Quectel Announces CC200A-LB Satellite Module for IoT Industries

March 15, 2023

Disney, Fox, Warner Bros. Discovery call off Venu sports streaming...

January 10, 2025

WWE agrees to merge with UFC to create a new...

April 5, 2023

Comcast to bundle Peacock, Netflix and Apple TV+ at a...

May 15, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

      May 31, 2025
    • Leadership Rotation Could Confirm Corrective Phase

      May 30, 2025
    • Run Your Stock Portfolio Like a Pro Sports Team

      May 30, 2025
    • U.S. foreign tax bill sends jitters across Wall Street

      May 30, 2025
    • Amazon taps Xbox co-founder to lead new team developing ‘breakthrough’ consumer products

      May 30, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,765 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,472 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,451 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,432 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,308 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,106)
    • Investing (538)
    • Stock (2,581)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right...

      May 31, 2025
    • Leadership Rotation Could Confirm Corrective Phase

      May 30, 2025
    • Run Your Stock Portfolio Like a Pro Sports Team

      May 30, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,106)
    • Investing (538)
    • Stock (2,581)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Levi Strauss to sell Dockers to...

    May 20, 2025

    On the sidelines of a pricier...

    May 5, 2024

    United Airlines CEO responds to string...

    March 20, 2024
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here